

Bertrand Allard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11838507/bertrand-allard-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28

papers

2,204

citations

18

h-index

30

g-index

30

ext. papers

2,768

ext. citations

7.3

avg, IF

5.49

L-index

#	Paper	IF	Citations
28	The adenosine pathway in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 611-629	19.4	101
27	On the mechanism of anti-CD39 immune checkpoint therapy 2020 , 8,		42
26	Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis. <i>Oncolmmunology</i> , 2019 , 8, 1601481	7.2	10
25	WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. <i>Oncolmmunology</i> , 2019 , 8, e1581545	7.2	9
24	Targeting the CD73-adenosine axis in immuno-oncology. <i>Immunology Letters</i> , 2019 , 205, 31-39	4.1	73
23	Targeting the adenosine pathway for cancer immunotherapy. <i>Seminars in Immunology</i> , 2019 , 42, 101304	10.7	37
22	Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays. <i>Methods in Enzymology</i> , 2019 , 629, 269-289	1.7	3
21	The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. <i>Immunological Reviews</i> , 2017 , 276, 121-144	11.3	414
20	A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. <i>Neoplasia</i> , 2017 , 19, 530-536	6.4	46
19	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. <i>Methods in Molecular Biology</i> , 2016 , 1458, 159-77	1.4	5
18	CD73-adenosine: a next-generation target in immuno-oncology. <i>Immunotherapy</i> , 2016 , 8, 145-63	3.8	82
17	CD73-adenosine reduces immune responses and survival in ovarian cancer patients. <i>Oncolmmunology</i> , 2016 , 5, e1127496	7.2	27
16	CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 158-66	12.9	121
15	Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration. <i>MAbs</i> , 2016 , 8, 1371-1385	6.6	6
14	Immunosuppressive activities of adenosine in cancer. <i>Current Opinion in Pharmacology</i> , 2016 , 29, 7-16	5.1	156
13	CD73 plays a protective role in collagen-induced arthritis. <i>Journal of Immunology</i> , 2015 , 194, 2487-92	5.3	27
12	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. <i>Cancer Immunology Research</i> , 2015 , 3, 506-17	12.5	198

11	Abstract 3361: CD73 expression on tumor-infiltrating breast cancer leukocytes 2015 ,		2
10	Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 863-81	6.4	30
9	Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. <i>Cancer Research</i> , 2014 , 74, 3652-8	10.1	178
8	Co-blockade of immune checkpoints and adenosine A receptor suppresses metastasis. <i>OncotImmunology</i> , 2014 , 3, e958952	7.2	18
7	Anti-CD73 therapy impairs tumor angiogenesis. <i>International Journal of Cancer</i> , 2014 , 134, 1466-73	7.5	108
6	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2013 , 5, 169-81	5.4	121
5	Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor. <i>MAbs</i> , 2013 , 5, 56-69	6.6	17
4	Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. <i>Clinical Cancer Research</i> , 2013 , 19, 5626-35	12.9	293
3	CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. <i>Journal of Biomedicine and Biotechnology</i> , 2012 , 2012, 485156		64
2	Electroporation-aided DNA immunization generates polyclonal antibodies against the native conformation of human endothelin B receptor. <i>DNA and Cell Biology</i> , 2011 , 30, 727-37	3.6	11
1	Kinetic Study of Human Full-Length Wild-Type JAK2 and V617F Mutant Proteins. <i>The Open Enzyme Inhibition Journal</i> , 2009 , 1, 80-84	0	5